Risk Factors for Cost-Related Delays to Medical Care Among Lymphoma Patients: A 22-Year Analysis of a Nationally Representative Sample
- 3 March 2021
- journal article
- research article
- Published by Elsevier BV in Clinical Lymphoma Myeloma and Leukemia
- Vol. 21 (7), e619-e625
- https://doi.org/10.1016/j.clml.2021.02.013
Abstract
No abstract availableThis publication has 31 references indexed in Scilit:
- Ibrutinib and Venetoclax for First-Line Treatment of CLLThe New England Journal of Medicine, 2019
- Medical financial hardship among cancer survivors in the United StatesCancer, 2019
- Interventions to Improve Medication AdherenceJAMA, 2018
- Financial Hardship Associated With Cancer in the United States: Findings From a Population-Based Sample of Adult Cancer SurvivorsJournal of Clinical Oncology, 2016
- For Working-Age Cancer Survivors, Medical Debt And Bankruptcy Create Financial HardshipsHealth Affairs, 2016
- Ibrutinib in Refractory Classic Hodgkin's LymphomaThe New England Journal of Medicine, 2015
- Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid LeukemiaThe New England Journal of Medicine, 2014
- Estimating The Health And Economic Burden Of Cancer Among Those Diagnosed As Adolescents And Young AdultsHealth Affairs, 2014
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic LeukemiaThe New England Journal of Medicine, 2013
- Adherence to MedicationThe New England Journal of Medicine, 2005